Evidence map›Paper›PMID 35440121›Full record

ArticleNature communications2022

Human serum triggers antibiotic tolerance in Staphylococcus aureus.

Elizabeth V K Ledger, Stéphane Mesnage, Andrew M Edwards

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Acquired mutations in transcriptional regulatorAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Host-driven remodelling of theMicrobiology (Reading, England) · 2026
    Review
  9. Unlocking the secret tomSystems · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. The innate immune protein calprotectin ablates the bactericidal activity of β-lactam antibiotics.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  17. Expression ofmBio · 2025
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elizabeth V K LedgerMRC Centre for Molecular Bacteriology and Infection, Imperial College London, Armstrong Rd, London, SW7 2AZ, UK.
Stéphane MesnageSchool of Biosciences, University of Sheffield, Sheffield, S10 2TN, UK.ORCID http://orcid.org/0000-0003-1648-4890
Andrew M EdwardsMRC Centre for Molecular Bacteriology and Infection, Imperial College London, Armstrong Rd, London, SW7 2AZ, UK. a.edwards@imperial.ac.uk.ORCID http://orcid.org/0000-0002-7173-7355
Imperial College London · GBUniversity of Sheffield · GB

Funding

Department of HealthNIAID NIH HHS HHSN272200700055CWellcome TrustWellcome Trust 203812/Z/16/Z
6 · The paper itself

Abstract

Staphylococcus aureus frequently causes infections that are challenging to treat, leading to high rates of persistent and relapsing infection. Here, to understand how the host environment influences treatment outcomes, we study the impact of human serum on staphylococcal antibiotic susceptibility. We show that serum triggers a high degree of tolerance to the lipopeptide antibiotic daptomycin and several other classes of antibiotic. Serum-induced daptomycin tolerance is due to two independent mechanisms. Firstly, the host defence peptide LL-37 induces tolerance by triggering the staphylococcal GraRS two-component system, leading to increased peptidoglycan accumulation. Secondly, GraRS-independent increases in membrane cardiolipin abundance are required for full tolerance. When both mechanisms are blocked, S. aureus incubated in serum is as susceptible to daptomycin as when grown in laboratory media. Our work demonstrates that host factors can significantly modulate antibiotic susceptibility via diverse mechanisms, and combination therapy may provide a way to mitigate this.

Indexed as

DaptomycinStaphylococcal InfectionsAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsDaptomycin

Identifiers

PMID35440121
PMCPMC9018823
OpenAlexW4225485337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.